IKT INHIBIKASE THERAPEUTICS INC Management Changes 8-K Filing 2025 - CEO Transition Inhibikase Therapeutics announced the resignation of CEO Milton H. Werner effective February 13, 2025, and the appointment of Mark Iwicki as the new CEO starting February 14, 2025, with Iwicki receiving a $710,000 salary and stock options totaling over 15 million shares.Get access to all SEC 8-K filings of the INHIBIKASE THERAPEUTICS INC